EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Outcomes of sequential third‐line therapies in patients with refractory overactive bladder

Po-Ming Chow iD, Tyler Trump, Howard B Goldman

International Journal of Urology · 2024

DOI: 10.1111/iju.15463 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Urology, 2024. Verfasst von Po-Ming Chow und 2 weiteren Autor:innen. Beteiligte Einrichtung: Glickman Urological Institute, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Urinary Bladder, Overactive, Botulinum Toxins, Type A. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Sacral neuromodulation (SNM) and onabotulinumtoxinA (BoNTA) injection are third‐line therapies for overactive bladder (OAB). Although the efficacy of each third‐line treatment has been well established in clinical trials, there is far less information about performing one third‐line therapy after the other. Our aim is thus to investigate the outcomes of post‐SNM BoNTA and post‐BoNTA SNM as “second” third‐line treatments.

Methods

We retrospectively reviewed all OAB patients who had both SNM and BoNTA between 2013 and 2022. The primary endpoint was the response rates (>50% improvements) of the second third‐line treatments. Secondary endpoints were the proportion of the patients who achieved total dry, the duration of treatments of patients who had significant responses, and risk factors that are associated with treatment response or duration of treatments.

Results

A total of 172 patients had two third‐line therapies. There were 104 patients who had post‐SNM BoNTA and 68 patients who had post‐BoNTA SNM. In the post‐SNM BoNTA group, 62.5% (65/104) had significant responses after BoNTA treatment. In the post‐BoNTA SNM group, 61.8% (44/68) had significant responses after SNM treatment. The proportions of patients who became dry were 21.2% and 23.5%, respectively. In the post‐SNM BoNTA group, spinal pathology is associated with a lower probability of a significant response (48.9% vs. 73.7%, p ‐value = 0.0105).

Conclusions

BoNTA or SNM remains a viable option for refractory OAB after patients fail from one another. Spinal pathology is associated with a poorer response of post‐SNM BoNTA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder, OveractiveBotulinum Toxins, Type AHumansRetrospective StudiesFemaleMaleMiddle AgedTreatment OutcomeAgedElectric Stimulation TherapyNeuromuscular AgentsAdultLumbosacral Plexus

Stichwörter der Autor:innen

botulinum toxinincontinenceoveractive bladdersacral neuromodulationurgency

Substanzen

Botulinum Toxins, Type Aonabotulinum toxin ANeuromuscular Agents

Autor:innen und Institutionen

  • Glickman Urological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • National Taiwan University Hospital and College of Medicine, Taipei, Taiwan.
  • National Taiwan University Hospital Hsin-Chu Branch, Zhubei City, Taiwan.

ORCID-Profile: Po-Ming Chow

Zitieren

APA

Chow, P. M., Trump, T., & Goldman, H. B. (2024). Outcomes of sequential third‐line therapies in patients with refractory overactive bladder. International Journal of Urology. https://doi.org/10.1111/iju.15463

Vancouver

Chow PM, Trump T, Goldman HB. Outcomes of sequential third‐line therapies in patients with refractory overactive bladder. International Journal of Urology. 2024. doi:10.1111/iju.15463

BibTeX
@article{Chow2024,
  author = {Chow, Po-Ming and Trump, Tyler and Goldman, Howard B},
  title = {Outcomes of sequential third‐line therapies in patients with refractory overactive bladder},
  journal = {International Journal of Urology},
  year = {2024},
  doi = {10.1111/iju.15463}
}
Kostenlos starten →